Please provide your email address to receive an email when new articles are posted on . In adults with Graves’ disease, the risk for Graves’ orbitopathy may be associated with increased levels of ...

Background: A 59-year-old woman with a history of nodular goiter developed thyrotoxic symptoms while on levothyroxine therapy. Her thyrotoxicosis persisted after levothyroxine withdrawal, so she was ...

Initial thyroid-stimulating immunoglobulin (TSI) levels and early initiation of treatment were found to predict TSI normalization in a recent study published in BMC Ophthalmology by Park and ...

Despite Graves' disease and Graves' orbitopathy affecting around 3 million Europeans and costing billions of euros, treatments can only control symptoms. INDIGO identified risk factors, studied ...

We carried out a randomized, double-blind, placebo-controlled trial to determine the effect of selenium (an antioxidant agent) or pentoxifylline (an antiinflammatory agent) in 159 patients with mild ...

VICTORIA, British Columbia — The addition of nonsteroidal intravenous (IV) mycophenolate to the recommended therapy of IV methylprednisolone significantly improves severe Graves' orbitopathy, with ...

Radioactive iodine (RAI) treatment was associated with an increased risk of developing Graves' orbitopathy (GO) in patients with thyroid cancer. Patients who developed GO received significantly higher ...

The prevalence of thyroid orbitopathy, compared with an estimate for the United Kingdom population, is examined in a large cohort of patients treated for periocular lymphoma. Clinical details were ...

Graves’ disease is the most common cause of hyperthyroid­ism and frequently causes changes to the eye and surrounding structures, including retraction of the eyelid, bulging of the eye, and restricted ...

Background A 59-year-old woman with a history of nodular goiter developed thyrotoxic symptoms while on levothyroxine therapy. Her thyrotoxicosis persisted after levothyroxine withdrawal, so she was ...